T he discovery of superoxide dismutasel provided a highly specific probe for the implication of the superoxide free radical (O2 ) in numerous biological processes. From the beginning, though, there were those who were disquieted by the rather robust nature of the damage that was apparently inflicted by this relatively mild-mannered radical. Soon, evidence suggested that superoxide radical was not acting alone but was, in fact, collaborating with hydrogen peroxide (the product of its dismutation) to is the hydroxyl radical. In some systems, the reactivity of the oxidant differs from that of radiolytically generated hydroxyl radical.89 Koppenol8 has suggested that Reaction 3 may alternatively be written as follows:
Fe+2+H202->FeO°+H2O
(4)
The ferryl ion (FeO+2) has oxidant properties similar to, but somewhat less potent than, hydroxyl radical. From a physiological or clinical perspective, the important point to appreciate is that iron may seriously exacerbate any oxidative stress. Of interest, higher organisms are particularly careful about how iron is handled. There is never any "free" or loosely chelated iron in the healthy state. It is transported in the ferric state, bound to transferrin, in a complex that is especially difficult to reduce. Likewise, it is stored in the ferric state by ferritin, a protein found in nearly all tissues and in plasma. Importantly, the superoxide radical is capable of reducing ferritinbound iron to the ferrous state, whereupon it is released.10,11 It is this iron, liberated by the pathological production of superoxide, that is now free to catalyze Haber-Weiss chemistry and to wreak additional cellular havoc.
A few chelating agents are known, notably desferrioxamine (deferoxamine or Desferal) and diethylenetriamine pentaacetic acid (DTPA or DETAPAC), that are capable of binding ferric iron extremely tightly and with such a shift in redox potential that the iron is biologically not reducible.12 Like superoxide dismutase, desferrioxamine has become a useful probe for detection of the involvement of iron in any circumstance producing biological injury.
In this issue of Circulation, Williams et a113 find that desferrioxamine treatment significantly improves functional and metabolic recovery of isolated, perfused rabbit hearts subjected to 30 minutes of global ischemia. An encouraging feature of their study is the finding that treatment at the time of reperfusion is nearly as effective for their end points as treatment begun before the onset of ischemia. This may bode well for the possible clinical application of this approach to coronary artery occlusion because the time of reperfusion is often controlled by the physician, whether by thrombolysis, angioplasty, or bypass surgery. (Although desferrioxamine is far from benign,14 it is approved for human use in the treatment of iron overload.) Of note, however, recent studies by Reddy et al'5 and Lesnefsky et al'6 used similar preischemia and prereperfusion dosing schedules in the open-chest dog model of regional ischemia, with assessment of infarct size as their end point. These investigators found a significant decrease in infarct size only in animals pretreated with the drug. Yet another study by Maxwell et al17 using an in vivo rabbit model failed to find any effect on infarct size, even with preischemic administration. Thus, as with nearly all interventions aimed at reducing myocardial reperfusion injury, this one is also controversial.
In 1985, Babbs'8 reported that desferrioxamine treatment doubled the probability of survival (from 31% to 62%) of rats subjected to 6-10 minutes of total circulatory arrest, followed by resuscitation. Myers et al19 found desferrioxamine protective in the isolated rabbit heart subjected to hypoxia and reoxygenation as evidenced by decreased release of creatine kinase. Subsequent studies in isolated, perfused rat hearts confirmed suppression of postischemic creatine kinase release20 and of reperfusion-induced arrhythmias. The potential use of desferrioxamine to improve recovery of transplanted organs has not escaped notice. A recent study by Menasche et a125 found that the addition of the drug to cardioplegic solution improved postreperfusion ventricular pressure development, maximal rate of rise of ventricular pressure, left ventricular compliance, and coronary flow. Green et a126 found that desferrioxamine reduced the susceptibility to lipid peroxidation in cold ischemic rabbit kidneys. Liver subjected to warm ischemia and reperfusion in vivo is protected substantially from lipid peroxidation and by histopathological evidence if desferrioxamine is administered at any time before reperfusion. 27 If "liberated" iron can seriously exacerbate the component of reperfusion injury due to free radical production, the question arises as to whether iron status from a nutritional standpoint may be a predisposing factor in ischemic heart disease. A study by van der Kraaij et a128 has addressed the question by comparing hearts from normal with those from ironsupplemented rats. Langendorff-prepared hearts were subjected to 45 minutes of anoxic perfusion, followed by reoxygenation. Under normoxia, the groups behaved identically. After a period of anoxia, however, the iron-loaded hearts displayed ventricular fibrillation and significantly lower recovery of contractility, both of which were returned to control values by perfusion with desferrioxamine.
If iron-overload imposes a risk to ischemic myocardial injury, does normal "iron sufficiency" also impose a risk? Maybe it does. J.L. Sullivan29 has proposed that iron status may be the key to understanding the gender difference in death rates from ischemic heart disease. Healthy young men have serum ferritin levels three or four times those of healthy young women, and this presumably reflects a similar difference in tissue stores of iron. The Framingham Study revealed that the risk of heart disease in women increased significantly after natural menopause, simple hysterectomy, or hysterectomy with bilateral oophorectomy. This suggests that regular menstrual blood loss (resulting in lower serum and tissue ferritin stores), rather than endogenous estrogen levels, may be the protective factor. The sex difference, Sullivan points out, is the most widely ignored of the major risk factors simply because it is viewed as a "nonmodifiable factor." Maybe it is not. Blood donation three times a year will lower the serum ferritin level of a man to that of a young woman.29 What may be bad news for the "Geritol generation" may be good news for the Red Cross. 
